Pharmacological hypothesis: Nitric oxide-induced inhibition of ADAM-17 activity as well as vesicle release can in turn prevent the production of soluble endothelin-converting enzyme.

Kuruppu, Sanjaya; Rajapakse, Niwanthi W; Parkington, Helena C; Smith, Ian

Kuruppu, Sanjaya; Rajapakse, Niwanthi W; Parkington, Helena C; Smith, Ian.

Afiliação

Kuruppu S; Department of Biochemistry & Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Rajapakse NW; Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria, 3004, Australia.
Parkington HC; Department of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Smith I; Department of Biochemistry & Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.

Pharmacol Res Perspect ; 5(5)2017 10.

Article em En | MEDLINE | ID: mdl-28971608

Assuntos

Proteína ADAM17/metabolismo; Enzimas Conversoras de Endotelina/metabolismo; Óxido Nítrico/farmacologia; Animais; Membrana Celular/metabolismo; Regulação para Baixo; Endotelina-1/metabolismo; Vesículas Extracelulares/efeitos dos fármacos; Vesículas Extracelulares/metabolismo; Humanos

Palavras-chave

Endothelin-converting enzyme; nitric oxide; protein kinase C; trafficking

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzimas Conversoras de Endotelina / Proteína ADAM17 / Óxido Nítrico Limite: Animals / Humans Idioma: En Revista: Pharmacol Res Perspect Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google